Publication:
Cpanet registry—an international chronic pulmonary aspergillosis registry

dc.contributor.authorLaursen, Christian B. (25643079200)
dc.contributor.authorDavidsen, Jesper Rømhild (12805232600)
dc.contributor.authorVan Acker, Lander (57194427235)
dc.contributor.authorSalzer, Helmut J.F. (36118318800)
dc.contributor.authorSeidel, Danila (57191968048)
dc.contributor.authorCornely, Oliver A. (57188644302)
dc.contributor.authorHoenigl, Martin (23090526000)
dc.contributor.authorAlastruey-Izquierdo, Ana (15834261700)
dc.contributor.authorHennequin, Christophe (7103009191)
dc.contributor.authorGodet, Cendrine (7005042297)
dc.contributor.authorBarac, Aleksandra (55550748700)
dc.contributor.authorFlick, Holger (16230091900)
dc.contributor.authorMunteanu, Oxana (26435358100)
dc.contributor.authorVan Braeckel, Eva (8265309200)
dc.date.accessioned2025-06-12T14:17:16Z
dc.date.available2025-06-12T14:17:16Z
dc.date.issued2020
dc.description.abstractChronic pulmonary aspergillosis (CPA) is a chronic fungal infection of the lung associated with high morbidity and mortality. The CPA Research network (CPAnet) registry established in 2018 is an international multicenter collaboration aiming to improve CPA knowledge and patient care. This study’s aim was to describe the data collection process and content of CPAnet registry with preliminary clinical data. In the CPAnet registry, clinical data are collected through a web-based questionnaire. Data include CPA phenotype, comorbidities, treatment, outcome, and follow-up from several international centers. An exemplary descriptive analysis was performed on 74 patients, who were registered online before April 2020. CPA patients were predominantly (72%) male, 39% had chronic obstructive pulmonary disease, and 68% had a history of smoking. Chronic cavitary pulmonary aspergillosis was the most common CPA subtype (62%). In 32 patients (52%), voriconazole was the preferred first-line therapy. The multicenter multinational CPAnet registry is a valuable approach to gather comprehensive data on a large study population and reflects real-world clinical practice rather than focusing on specific patient populations in more specialized centers. Additional CPA reference centers are being encouraged to join this promising clinical research collaboration. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
dc.identifier.urihttps://doi.org/10.3390/jof6030096
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85087374864&doi=10.3390%2fjof6030096&partnerID=40&md5=3e8434d6f9d28f0ea004e21d866b4bdb
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/4815
dc.subjectAntifungals
dc.subjectAspergillus
dc.subjectChronic pulmonary aspergillosis
dc.subjectCPAnet
dc.subjectDiagnosis
dc.subjectInternational collaboration
dc.subjectRegistry
dc.subjectTreatment
dc.titleCpanet registry—an international chronic pulmonary aspergillosis registry
dspace.entity.typePublication

Files